Access to End-of-Life Medicines in Care Homes: Barriers, Variability and Opportunities for Improvement
A UK-wide survey of care home professionals reveals that significant delays in accessing controlled drugs for end-of-life care stem from fragmented pathways and staffing shortages, leading to a strong consensus that implementing on-site centralised stock—provided with robust governance and training—could substantially improve timely symptom management.